expect high link see miss come
addit fy guidanc cut notabl ostens reflect acknowledg
appli higher discount certain guidanc assumpt probabl accordingli
bia could upsid time issu howev get
benefit doubt given recent execut
expect revenu approxim translat miss
vs consensu y/i growth vs compani guidanc /- y/i growth
manag assert compon miss rel intern target
follow popul genom due larg delay time
sizeabl sequenc system consum purchas dtc market pressur
larg array servic due lower expect sale non-
high throughput note detail provid oper perform
suspect may materi opportun reduc expens vs
origin plan accordingli ep miss could
revenu expect approxim prior guidanc approxim
effect manag cut full year revenu guidanc
extens revenu guidanc effect fulfil investor
concern full year guidanc quit back-end weight manag attribut
reduct follow expect sequenc consum revenu growth
y/i sequenc servic revenu declin slightli y/i overal sequenc
revenu growth y/i total microarray revenu declin y/i
primarili due dtc notabl expect novaseq placement remain unchang
note preview link didnt see path big beat quarter howev
also think lot risk rel consensu forecast believ key
driver us miss know manag bank
major popul sequenc program meet novaseq target
notabl hard forecast manag chang guidanc practic popgen
move forward thought adequ captur dtc headwind
assum y/i declin like bad forecast manag
also chang practic clear us partner forecast need
discount higher rate expect benchtop revenu
essenti move sideway q/q surpris weak beyond
novaseq especi nextseq although manag point cdx time
dynam await detail full compani evalu somewhat
educ guess pend detail manag
continu page
pleas see page report import disclosur
well posit maintain leadership expand high-end genet
tool research market drive robust growth nipt market increasingli displac
exist diagnost establish reimburs act arm dealer
elimin barrier sequenc becom increasingli use oncolog adjac
market believ factor continu translat robust doubl digit revenu
earn growth justifi premium valuat
nextseq key growth driver
continu evolv favor
nextseq placement continu increas
new instruments/kit surpris
sourc revenu
expand use sequenc increas
becom much favor
novaseq unabl catalyz
strength nextseq placement
concern build oper leverag
slow materi
hiseq bigger expect headwind
leader genet tool segment tool diagnost market
segment compani broad portfolio system consum analysi tool
design simplifi genet analysi address rang genom complex price
point throughput enabl research select best solut scientif
challeng market leader next gener sequenc increasingli focus
reproduct health includ nipt act arm dealer emerg oncolog
reduc total revenu forecast servic
novaseq consum mostli due cut placement cadenc placement
novaseq instrument product balanc
reduct function dtc pressur cut total microarray revenu forecast
reduc ep forecast look ahead
cut revenu forecast due chang
novaseq pace major carri forward larg poor trend
implicit outlook mani product/servic line assumpt
could prove conserv compani seem indic heavili
discount probabl nih/gel us howev seem appropri
given recent disappoint trend poor manag execution/forecast rel
targets/commun past quarter addit worth note
risk arguabl get enough attent deal bgi
competit nipt patent pool silver line favor
comparison still look well posit gener mdd revenu growth
bad news path earn seem lot less like cut
ep forecast prior consensu
dcf support price object believ hard assign much
multipl ep least near term given recent track
record on-going concerns/uncertainti get us split
differ cut price target pend addit detail
like better perform certainli would expect yield much
stock appreci hard explain anyway past month
see share trade lot closer ytd low high earn ultim
type pullback repres tremend opportun purchas given ilmn
market leadership tremend associ genet tool said
execut visibl need get lot better
compani report cowen compani
yr cagrcomments/guidancetot revenu guid y/i product classproduct inst servic incl nextbio revenu geographyamerica middl east growth y/i middl east revenu growth expect almost headwind salesproduct middl east sequenc guid y/i mid-teen growth revenu growth total servic revenu guid slightli y/yservic revenu growth microarray guid y/i flat growth revenu growth total revenu growth wors anticip apr expect mid-teen y/i comment purchas instrument lh array system strength partial function scale lhcowen comment relat instrument maint contract remaind nipt popgen core ip/licens oncolog collabor cowen comment manag indic largerli consum littl mainten believ largerli ancestri com cowen
compani report thomson eikon cowen compani
mm except per share guidancenet revenu guid y/i gener oper opex increas q/q percentag sale opex vs non-oper interest incom declin q/q due debt repaymentearn guid loss attribut nci add helix dilut expect earn per ep includ helix dilutionshar gross op fy expect declin slightli y/i due lower margin popgen oncolog collabor revenu q/q cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit greater-than-expect reduct academ
govern research fund competit commerci avail potenti
disrupt technolog price pressur caus competit increas demand
lower-pr instrument run-tim cost neg regulatori dynam
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc juli et dissemin juli et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
